New treatment shows promise for rare skin lymphoma in chinese patients

NCT ID NCT05442554

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 26 times

Summary

This study looked at the long-term side effects and effectiveness of a drug called brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma (CD30-positive cutaneous T-cell lymphoma). Participants received the drug through a vein every 21 days for up to 16 cycles. The goal was to see if the treatment could shrink or eliminate tumors for at least 4 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.